
News|Articles|May 1, 2002
Health systems/plans share common coverage vision for Clarinex, OTC Claritin
Last month the FDA's Nonprescription Drugs Advisory Committee unanimously supported loratadine's (Claritin, Schering-Plough) switch from prescription to over-the-counter status for treatment of chronic idiopathic urticaria, moving the drug one step closer to full OTC status (see significant event timeline in sidebar).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
2
UC Davis develops new drug for bladder cancer patients
3
The FDA proposes ditching comparative efficacy studies for biosimilars
4
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
5

















































